LONDON (Reuters) - European health regulators said on Friday they had recommended approval of a drug for advanced lung cancer developed by Swiss drugmaker Novartis that is intended to treat patients with a specific genetic mutation.
from
from
ليست هناك تعليقات :
إرسال تعليق